Akèy › Kansè ovè › Kalifòni › Los Angeles
Etid klinik pou Kansè ovè nan Los Angeles, CA
50 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Los Angeles
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Ap rekriteFaz 2/3
- Cedars-Sinai Medical Center, Los Angeles
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- University of California - Los Angeles, Los Angeles
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Ap rekriteFaz 2
- Start Los Angeles /ID# 281533, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Los Angeles
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- UCLA - University of California Los Angeles Medical Center /ID# 274566, Los Angeles
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
- Research Site, Los Angeles
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- UCLA Hematology/Oncology - Westwood (Building 100), Los Angeles
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- Valkyrie Clinical Trials, Los Angeles
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 2
- University of California, Los Angeles Medical Center, Los Angeles
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 2
- Cedars Sinai Medical Center, Los Angeles
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Southern California, Los Angeles
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Ap rekriteFaz 1/2
- Start Cal, Los Angeles
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Ap rekriteFaz 1
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Children's Hospital Los Angeles, Los Angeles
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Ap rekriteFaz 1
- Valkyrie Clinical Trials, Los Angeles
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Ap rekriteFaz 1
- START - Los Angeles, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- Keck Medicine of USC Koreatown, Los Angeles
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- ak 3 plis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- Los Angeles Cancer Network, Los Angeles
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UCLA - Hematology/Oncology Clinical Research Unit, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of California Los Angeles Medical Center, Los Angeles
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Ap rekriteFaz 1
- START Los Angeles, Los Angeles
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Ap rekriteFaz 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Ap rekriteFaz 1/2
- University of Southern California, Los Angeles
- UCLA, Los Angeles
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Ellison Clinic at Saint John's, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
EXoPERT EMERALD Clinical Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- City of Hope Duarte Cancer Center, Los Angeles
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ap rekriteFaz 2
- GSK Investigational Site, Los Angeles
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- UCLA Medical Center, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Ap rekriteFaz 1
- Start Lacn, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- Oncology Institute for Hope and Innovation, Los Angeles
Access to Genetic Testing in Underserved Patients With Cancer
Ap rekriteVolontè an sante akeyi
- USC / Norris Comprehensive Cancer Center, Los Angeles
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Ap rekriteFaz 1
- UCLA - JCCC Clinical Research Unit, Los Angeles
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- USC - Norris Comprehensive Cancer Center, Los Angeles
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
- UCLA - JCCC Clinical Research Unit, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Southern California, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Cedars Sinai Medical Center, Los Angeles
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- MiraKind, Los Angeles
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
- Pittsburgh, PA30 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)74 etid
- Kansè nan tete73 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
- Kansè tete negatif triple27 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.